INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART

NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holding Corporation ("Integra" or the "Company") (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

PRNewsWire • 10 hours ago

Did You Lose Money on Integra LifeSciences Holdings Corporation Stock? The Law Offices of Howard G.

BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Integra LifeSciences Holdings Corporation ("Integra" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Integra LifeSciences Holdings Corporation (NASDAQ: IART) investors into whether the Company may have violated the federal securities laws. The investigation comes after a October 2, 2026 disclosure c.

Business Wire • Oct 23, 2026

Lost Money on Integra LifeSciences Holdings Corporation Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 21.2% Share Price Drop

LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Integra LifeSciences Holdings Corporation ("Integra" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Integra LifeSciences Holdings Corporation (NASDAQ: IART) investors into whether the Company may have violated the federal securities laws. The investigation follows the October 2, 2026 disclosure regarding Integra.

Business Wire • Oct 23, 2026

Integra LifeSciences: Progress Remains Frustratingly Slow, But Valuation Is Getting Interesting

Integra LifeSciences remains pressured by operational challenges, but restructuring and a returning CEO offer renewed turnaround potential. IART's Wound Reconstruction business continues to underperform, though upcoming product relaunches and market normalization could drive recovery. Valuation appears undemanding, with EBITDA margin expected to exceed 20% in 2025 and double-digit FCF margins possible by 2028.

Seeking Alpha • Oct 23, 2026

Lost Money on Integra LifeSciences Holdings Corporation Shares? The Law Offices of Frank R.

LOS ANGELES--(BUSINESS WIRE)--Integra LifeSciences Holdings Corporation ("Integra" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Integra LifeSciences Holdings Corporation (NASDAQ: IART), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Integra LifeScience.

Business Wire • Oct 22, 2026

What Integra LifeSciences (IART) Said on Its Q3 Earnings Call

Integra LifeSciences NASDAQ: IART reported third-quarter revenue at the low end of its guidance range as a flooding-related disruption at its Cincinnati facility and slower-than-expected Tissue Reconstruction performance weighed on results. The company said strength in neurosurgery and international Specialty Surgery partially offset those pressures.

MarketBeat • Oct 21, 2026

Integra LifeSciences Holdings Corporation (IART) Q3 2026 Earnings Call Transcript

Integra LifeSciences Holdings Corporation (IART) Q3 2026 Earnings Call Transcript

Seeking Alpha • Oct 21, 2026

Integra LifeSciences Reports Third Quarter 2026 Financial Results

PRINCETON, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2026.

GlobeNewsWire • Oct 21, 2026

Integra LifeSciences Holdings Corporation Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your IART Investments

New York, New York--(Newsfile Corp. - October 21, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices. [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Happened?

Newsfile Corp • Oct 21, 2026

Integra LifeSciences (IART) Surpasses Q3 Earnings Estimates

Integra LifeSciences (IART) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.54 per share a year ago.

Zacks Investment Research • Oct 21, 2026